JP5981138B2 - 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用 - Google Patents

結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用 Download PDF

Info

Publication number
JP5981138B2
JP5981138B2 JP2011519186A JP2011519186A JP5981138B2 JP 5981138 B2 JP5981138 B2 JP 5981138B2 JP 2011519186 A JP2011519186 A JP 2011519186A JP 2011519186 A JP2011519186 A JP 2011519186A JP 5981138 B2 JP5981138 B2 JP 5981138B2
Authority
JP
Japan
Prior art keywords
polypeptide
sequence
seq
tuberculosis
rv2386c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011519186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528896A5 (enExample
JP2011528896A (ja
Inventor
ブラウン，ジェームズ
メッテンス，パスカル
マーフィー，デニス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2011528896A publication Critical patent/JP2011528896A/ja
Publication of JP2011528896A5 publication Critical patent/JP2011528896A5/ja
Application granted granted Critical
Publication of JP5981138B2 publication Critical patent/JP5981138B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
JP2011519186A 2008-07-25 2009-07-24 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用 Active JP5981138B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8369908P 2008-07-25 2008-07-25
US61/083,699 2008-07-25
PCT/EP2009/059585 WO2010010179A1 (en) 2008-07-25 2009-07-24 The tuberculosis rv2386c protein, compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134587A Division JP6104326B2 (ja) 2008-07-25 2015-07-03 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2011528896A JP2011528896A (ja) 2011-12-01
JP2011528896A5 JP2011528896A5 (enExample) 2012-09-06
JP5981138B2 true JP5981138B2 (ja) 2016-08-31

Family

ID=41227131

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011519186A Active JP5981138B2 (ja) 2008-07-25 2009-07-24 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用
JP2015134587A Expired - Fee Related JP6104326B2 (ja) 2008-07-25 2015-07-03 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015134587A Expired - Fee Related JP6104326B2 (ja) 2008-07-25 2015-07-03 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用

Country Status (23)

Country Link
US (4) US20110206712A1 (enExample)
EP (1) EP2315834B1 (enExample)
JP (2) JP5981138B2 (enExample)
KR (1) KR20110049834A (enExample)
CN (2) CN106866801A (enExample)
AU (1) AU2009273132B2 (enExample)
BR (1) BRPI0916704A2 (enExample)
CA (1) CA2731547C (enExample)
CO (1) CO6351811A2 (enExample)
CY (1) CY1121632T1 (enExample)
DK (1) DK2315834T3 (enExample)
EA (1) EA201100070A1 (enExample)
ES (1) ES2685498T3 (enExample)
HR (1) HRP20181353T1 (enExample)
HU (1) HUE039159T2 (enExample)
IL (1) IL210589A (enExample)
LT (1) LT2315834T (enExample)
MX (1) MX2011000982A (enExample)
PL (1) PL2315834T3 (enExample)
PT (1) PT2315834T (enExample)
SI (1) SI2315834T1 (enExample)
UA (1) UA107329C2 (enExample)
WO (1) WO2010010179A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016000734A (ja) * 2008-07-25 2016-01-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428801B1 (en) * 2006-03-14 2014-05-07 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
US20110189217A1 (en) * 2008-06-26 2011-08-04 Barry Michael A Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
WO2010010180A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. Novel compositions and methods
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN107478849B (zh) * 2013-05-31 2019-08-20 中国医学科学院病原生物学研究所 用于结核病诊断和预防的蛋白
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
EP3180353B1 (en) 2014-08-15 2021-09-22 Oxford Immunotec Limited Mycobacterium tuberculosis proteins
CN105572352B (zh) * 2016-02-17 2017-07-28 遵义医学院附属医院 一组结核潜伏感染诊断标志物及其用途
MX2019006728A (es) 2016-12-07 2019-12-02 Glaxosmithkline Biologicals Sa Nuevo proceso.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
DE112018002827T5 (de) 2017-05-30 2020-04-09 Glaxosmithkline Biologicals S.A. Neue Verfahren zur Herstellung eines Adjuvans
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN108950031A (zh) * 2018-06-29 2018-12-07 周琳 结核分枝杆菌的利福平耐药性诊断标志物及其应用
CN109234414B (zh) * 2018-06-29 2022-05-17 周琳 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用
CN108866213A (zh) * 2018-06-29 2018-11-23 周琳 结核分枝杆菌利福平耐药性诊断标志物及其应用
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
EP3983011A1 (en) * 2019-06-14 2022-04-20 Statens Serum Institut Fusion proteins for tuberculosis vaccines
CN112457410B (zh) * 2020-11-05 2023-04-07 迈克生物股份有限公司 用于结核分枝杆菌感染检测的抗原组合物
DE202022102137U1 (de) 2022-04-21 2022-04-28 Damayanthi Dalu Eine neue Zusammensetzung zur Behandlung von Tuberkulose
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
CN115725607B (zh) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) 一种鼻疽诺卡菌的致病靶基因及其应用
CN120058854A (zh) * 2025-03-05 2025-05-30 北京知筹科技有限公司 一种调节低密度脂蛋白受体相关蛋白（lrp）的多肽及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
IL138809A0 (en) 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO2001098460A2 (en) 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
KR101178776B1 (ko) 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
SI2426141T1 (sl) * 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Postopek za preprečevanje ali zdravljenje infekcije z M tuberculosis
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
LT2315773T (lt) 2008-07-25 2016-11-10 Glaxosmithkline Biologicals S.A. Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui
WO2010010180A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. Novel compositions and methods
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
PL2315834T3 (pl) 2008-07-25 2018-12-31 Glaxosmithkline Biologicals S.A. Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania
DK2421557T3 (en) 2009-04-24 2019-03-25 Statens Seruminstitut TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
AU2011209399B2 (en) 2010-01-27 2014-04-10 Glaxo Group Limited Modified tuberculosis antigens

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016000734A (ja) * 2008-07-25 2016-01-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用

Also Published As

Publication number Publication date
IL210589A (en) 2015-05-31
US9480735B2 (en) 2016-11-01
EA201100070A1 (ru) 2011-10-31
HUE039159T2 (hu) 2018-12-28
PL2315834T3 (pl) 2018-12-31
CN102165064B (zh) 2017-06-20
UA107329C2 (uk) 2014-12-25
PT2315834T (pt) 2018-08-10
AU2009273132A1 (en) 2010-01-28
JP6104326B2 (ja) 2017-03-29
LT2315834T (lt) 2018-09-10
CY1121632T1 (el) 2020-07-31
JP2016000734A (ja) 2016-01-07
JP2011528896A (ja) 2011-12-01
MX2011000982A (es) 2011-03-02
US20140314802A1 (en) 2014-10-23
BRPI0916704A2 (pt) 2020-08-18
KR20110049834A (ko) 2011-05-12
CA2731547C (en) 2019-04-30
AU2009273132B2 (en) 2015-09-03
HRP20181353T1 (hr) 2018-10-19
EP2315834A1 (en) 2011-05-04
WO2010010179A1 (en) 2010-01-28
US20170065697A1 (en) 2017-03-09
DK2315834T3 (en) 2018-08-20
US20110206712A1 (en) 2011-08-25
CN102165064A (zh) 2011-08-24
US20140086948A1 (en) 2014-03-27
CA2731547A1 (en) 2010-01-28
EP2315834B1 (en) 2018-06-13
ES2685498T3 (es) 2018-10-09
IL210589A0 (en) 2011-03-31
US10286053B2 (en) 2019-05-14
CN106866801A (zh) 2017-06-20
CO6351811A2 (es) 2011-12-20
SI2315834T1 (sl) 2018-09-28

Similar Documents

Publication Publication Date Title
JP6104326B2 (ja) 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用
JP5873332B2 (ja) 新規化合物および方法
JP5824360B2 (ja) 新規化合物および方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150714

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150918

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160728

R150 Certificate of patent or registration of utility model

Ref document number: 5981138

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250